RxDoctor Payments Data

John Snell, DO

Internal Medicine · Louisville, KYNPI 1275528739

Payments from drug & device makers

$209in general payments, 2019–2025

Across 10 payments — averaging $20.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Phathom Pharmaceuticals, Inc.$97
  • Novartis$47
  • GSK$15
  • Johnson & Johnson$13
  • E.r. Squibb & Sons, L.L.C.$12
  • Lilly USA, LLC$12
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$18588%
  • Education$2412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$209 in reported general payments places this provider in the 40th percentile of 1,284 internal medicine providers in Kentucky.

See all internal medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$247,159
Medicare patients
447
Services billed
3,986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide181$221,547
EliquisApixaban151$166,343
JardianceEmpagliflozin93$142,250
OzempicSemaglutide113$112,167
JanuviaSitagliptin Phosphate83$93,513
XareltoRivaroxaban51$60,612
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$40,753
TrulicityDulaglutide23$38,043
Tresiba Flextouch U-100Insulin Degludec61$29,640
Spiriva HandihalerTiotropium Bromide24$22,796
LinzessLinaclotide19$19,022
Janumet XrSitagliptin Phos/Metformin Hcl12$14,989
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$7,507
SymbicortBudesonide/Formoterol Fumarate14$6,801
Atorvastatin Calcium855$5,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$12$259,589204 claims
Johnson & JohnsonXarelto$13$60,61251 claims
GSKTrelegy Ellipta$15$40,75352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,284 internal medicine providers in Kentucky.

Other internal medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →